Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  sorafenib tosylate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 325 for your search:
Start Over
Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 14898, HATT, NCT01098760
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 20 to 75
Sponsor: Other
Protocol IDs: ONC-2010-19, NCT01203787
Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181203, DARENCA STUDY 2, NCT01339962
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11213, NCT00073307
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02978, E2603, U10CA021115, U10CA180820, ECOG-E2603, NCT00110019
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 100554, 2004-001773-26, NCT00105443
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11868, NCT00111020
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00534, CAN-NCIC-E2805, SWOG-E2805, ECOG-E2805, CDR0000478976, CALGB-E2805, E2805, U10CA180820, U10CA021115, NCT00326898
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K1-404, B1771003, NCT00474786
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 12750, NCT00478114
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11721, NCT00494299
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12414, 2008-001087-36, NCT00692770
Sequential Study to Treat Renal Cell Carcinoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: 09072008-13772, EudraCT 2008-005011-18, NCT00732914
First Line Hepato Cellular Carcinoma (HCC)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA182-033, EUDRACT # 2008-003533-24, NCT00858871
A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 13266, 2008-006914-62, NCT00863746
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12917, 2008-006021-14, NCT00901901
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4061051, 2010-018585-23, NCT00920816
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 14295, 2009-012007-25, NCT00984282
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01981, ECOG-E1208, CDR0000657952, E1208, U10CA180820, U10CA021115, NCT01004978
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AV-951-09-301, NCT01030783
Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: CDR0000666232, FFCD-PRODIGE-11, FFCD-0803, EUDRACT-2009-015785-64, EU-21005, FFCD-PRODIGE 11 – 0803, NCT01075555
An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AV-951-09-902, 2009-015987-32, NCT01076010
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A2302, 2009-015459-25, NCT01223027
Start Over